Summary. The effect of two structurally unrelated aldose reductase inhibitors, sorbinil and ponalrestat, on glomerular prostaglandin production and urinary albumin excretion was investigated in rats with diabetes induced by streptozotocin. it was found that both aldose reductase inhibitors, when administered from the time of induction of the diabetes, significantly decreased the raised urinary albumin excretion in the diabetic rats, although it remained elevated compared with non-diabetic rats. Glomerular prostaglandin E and 6-ketoprostaglandin F,c~ production was significantly increased in glomeruli obtained from the diabetic rats. Inhibition of aldose reductase caused a reduction in the raised glomerular prostaglandin production, although this remained above that observed in the non-diabetic rats. Subsequent experiments were performed to determine whether the effects of the aldose reductase inhibitors could be explained by effects on glomerular filtration rate. It was found that ponalrestat, at a dose which markedly reduced urinary albumin excretion, did not significantly affect glomerular filtration rate in nondiabetic rats, rats with untreated streptozotocin-induced diabetes and rats with diabetes partially treated with low dose insulin. Glomerular sorbitol concentrations were significantly elevated in untreated diabetic rats as early as two weeks after the induction of diabetes. It is concluded that the administration of aldose reductase inhibitors from the time of induction of diabetes significantly reduces glomerular prostaglandin production and urinary albumin excretion. The latter effect is not due to an effect on glomerular filtration rate. Increased polyol pathway activity may account in part for the increased glomerular prostaglandin production and urinary albumin excretion in early experimental diabetes.
A number of functional and biochemical changes have been demonstrated in early diabetes in humans and in experimental animals which have been postulated to lead to the later development of the structural changes that characterise diabetic nephropathy. These include increased glomerular filtration rate (GFR) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] , increased urinary albumin excretion (UAE) [13] [14] [15] [16] [17] , increased production of vasoactive prostaglandins (PGs) by renal glomeruli [10, [18] [19] [20] , and increased glomerular sorbitol accumulation [21] . Although there are several plausible ways in which these changes could be related, the data linking these phenomena have been conflicting and confusing. For example, studies using aldose reductase inhibitors (ARI) to inhibit sorbitol accumulation have been reported to prevent the increased GFR and reduce the albuminuria seen in rats with diabetes induced by streptozotocin (STZ) [17] , or to have no effect on either parameter [16] , or to reduce the raised GFR but by effects apparently independent of reduction in sorbitol levels [22] . Moreover, the role of elevated PG production in the hyperfiltration and albuminuria seen in early diabetes in rats has been debated with conflicting conclusions [10, [18] [19] [20] 23] . Finally, although aldose reductase inhibition with sorbinil has been found to reduce glomerular PG production, it has been concluded that this is not due to aldose reductase inhibition per se [22] , allowing no conclusions concerning whether increased PG production is dependent on increased activity of the aldose reductase pathway.
This manuscript addresses some of these issues. Specifically, the effect of two structurally unrelated aldose reductase inhibitors on glomerular PG production and UAE is studied. Experiments showing that effects on UAE are not due to altered GFR are also reported, indicating an influence of experimental diabetes and aldose reductase inhibition on permeability of the glomeruli to albumin independent of GFR. 
Materials and methods

Maintenance of rats and induction of diabetes mellitus
Male Sprague-Dawley rats weighing 100-120 g at the commencement of each experiment were allowed free access to commercial chow (Gr2 +, Clark, King and Co., Melbourne, Victoria, Australia) and tap water. and centrifuged six times for one min at 1500 g. Preparations with minimal tubule contamination (<5%) were placed on ice for 90 min. Aliquots of approximately 5000 glomeruli were pipetted into capped microtubes and incubated in a gentle shaking water bath at 37 ~ 100 oscillations per min for 20 min. Arachidonic acid (Sigma Chem. Co.) was added to half the microtubes in the first experimental protocol to give a final concentration of 5 x 10 -5 mol/1, and angiotensin II was added to half the microtubes in the second experimental protocol to give a final concentration of 10-6 mol/1. The incubation was terminated after 20 rain by embedding the microtubes in ice before centrifugation for 45 s at 15000 g. Supernatants and pellets were separated and stored at -20 ~ for subsequent prostanoid and DNA assays respectively. Values shown are mean and SEM. There were six rats per group except for DS (five rats). D group was significantly higher than all the other groups (p < 0.01), which were not significantly different from each other
Isolation and incubation of glomeruli
Glomerular filtration rate (GFR)
GFR was determined using technetium 99m diethylene triamine pentacetic acid (DTPA) injection, as described and validated previously [12, 24] . The procedure is performed in conscious rats, and can be repeated in the same animals (in this case, at two weeks and four weeks).
Assays
Total PGE activity and 6-keto-PGF~a activity were determined by radioimmunoassay using reagents obtained from Advanced Magnetics Inc. (Cambridge, Mass., USA). The PGE antibody showed 100% cross-reactivity for PGE1 and PGEz. DNA was measured by the fluorimetric method of Downs and Wilfinger [25] . The urinary albumin concentration was measured by coated-tube radioimmuno, assay [24] . The preparation of tissue for sorbitol measurement was modified from the method of Chan et al. [26] . A large volume of methanolic HC1 was used to allow sufficient penetration of the kidney sample with homogenisation, and the amount of KHCO3 was increased to ensure the solution remained at pH 9.2 until quantified by fluorimetry. The sorbitol assay was based on the method described by Williams-Ashman [27] .
Experiments performed
Four separate experiments were performed. The first two experiments tested the effect of sorbinil and ponalrestat respectively in diabetic or control rats over a period of two and three weeks respectively. UAE and glomerular PG production were measured (in the first experiment, only PGE was measured, in the second experiment both PGE and 6-keto-PGFlcc).
In the third experiment the effect of ponalrestat on GFR and UAE was tested in normal and diabetic rats over a period of two and Solid bars -basal production, hatched bars -production in presence of 5 x 10-s mol/l arachidonic acid. There were six rats per group except for DS (five rats). D group was significantly higher than N and NS (p < 0.01) and DS was significantly lower than D and higher than N and NS O~ <-0.05) four weeks to determine whether its effects on UAE were attributable to an effect on GFR. Because partial insulin treatment has been described to prolong the period of hyperfiltration, the effect of ponalrestat on GFR and UAE was also determined in STZ-diabetic rats receiving 2 U/kg Ultratard HM (CSL-Novo, Melbourne, Victoria, Australia).
In the fourth experiment, gtomeruli were harvested from control and diabetic rats after two weeks diabetes to determine whether the glomerular sorbitol concentration was elevated in diabetic rats at this time point.
Statistical analysis"
All results were expressed as mean • SEM. Each experiment was analysed by one way analysis of variance, and where significant dif-227 ferences between groups were found, individual group comparisons were made using the Student's t-test for unpaired samples.
Results
The effect of sorbinil treatment on renal cortical sorbitol content, UAE and glomerular PGE production in non-diabetic and diabetic rats
The characteristics of the four groups of rats in the first experiment are shown in Table 1 . It can be seen that the diabetic rats were significantly lighter and were markedly hyperglycaemic. Sorbinil treatment had no effect on either parameter.
The sorbitol content of the renal cortex from untreated diabetic rats was markedly elevated (Fig. 1) . Sorbinil had no effect on the sorbitol content of non-diabetic rats, but prevented the increase in renal cortical sorbitol in diabetic rats.
UAE was markedly elevated in untreated diabetic rats (Fig. 2) . Sorbinil had no effect on UAE in non-diabetic rats, but significantly reduced the elevated UAE in the diabetic rats, although it remained significantly above that in the non-diabetic rats.
PGE production by isolated glomeruli was significantly elevated in glomeruli from untreated diabetic rats (Fig. 3) . Sorbinil treatment of the diabetic rats significantly reduced the production of PGE by their isolated glomeruli, although this remained significantly elevated compared with the non-diabetic rats. Sorbinil had no effect on PGE production by glomeruli from non-diabetic rats. The addition of arachidonic acid (5 x 10 -5 mol/1) to the isolated glomeruli increased PGE production to a similar Table 2 . Plasma glucose, body mass, renal cortical sorbitol content, urinary albumin excretion (UAE) and kidney mass in experiment 2 (ponalrestat treatment) at time of killing Table 3 . Production of prostagtandin E (PGE) and 6-keto-PGFlc~ by glomeruli isolated from non-diabetic and diabetic rats treated with vehicle alone or ponalrestat 
The effect of ponalrestat treatment on renal cortical sorbitol content, UAE, glomerular PGE and 6-keto-PGFlo~ production and kidney size in non-diabetic and diabetic rats
The characteristics of the four groups of rats in the second experiment are shown in Table 2 . This table also shows the renal cortical sorbitol content, UAE and kidney size in the four groups. It can be seen that, as with sorbinil, ponalrestat treatment was effective in preventing the rise in the renal cortical sorbitol content in the diabetic rats. This was associated with a significant reduction in UAE in the diabetic rats treated with ponalrestat. The kidney mass and the kidney mass as a percentage of body mass was not significantly affected by ponalrestat treatment. The production of PGE and 6-keto-PGFlo~ both basally and following stimulation with angiotensin II by glomeruli isolated from the four groups of rats is shown in Table 3 . It can be seen that as in the first experiment the production of PGE was increased in glomeruli from diabetic rats under basal conditions. 6-keto-PGFlCZ production was also increased. In glomeruli from the diabetic rats treated with ponalrestat, production of both prostanoids was reduced significantly, but remained significantly elevated above that seen in the non-diabetic rats. Incubation of the glomeruli with angiotensin II 10 -6 tool/1 resulted in significant stimulation of PGE and 6-ketoPGFlCZ production. The proportional stimulation over basal was much greater in the glomeruli from the nondiabetic rats (4-5 fold) than in the diabetic rats (less than two-fold) with intermediate fold stimulation in the glomeruli from the diabetic rats treated with ponalrestat (2-3 fold). The production of PGE and 6-keto-PGFlO~ in the presence of angiotensin II was similar in all groups, except for a significant reduction in the production of PGE in the diabetic group not treated with ponalrestat (Table 3) .
The relationship between UAE and GFR in non-diabetic and diabetic rats with and without ponalrestat or low dose insulin treatment
The plasma glucose and body mass of the rats in the third experiment at two weeks and four weeks are shown in Table 4 . It can be seen that treatment with insulin led to normal weight gain and intermediate plasma glucose between the non-insulin treated diabetic rats and the nondiabetic rats.
The UAE in the four groups of rats at the two time points is shown in Figure 4 and the GFR in Figure 5 . It is apparent that insulin treatment prevented the progressive rise in UAE. As in the second experiment (Table 2) , ponalrestat treatment decreased the increase in UAE in the non-insulin-treated diabetic rats, but did not restore it to the level seen in non-diabetic rats.
Normalisation of the UAE for the GFR (Table 5 ) showed that the diabetic rats still exhibited a marked increase in UAE for a given GFR. Ponalrestat treatment of diabetic rats restored the normalised UAE to that of non- . Glomerular filtration rate (GFR) in the six groups of rats described in Figure 4 . There was no significant effect of ponalrestat (P) treatment in the diabetic (D) rats, whether insulin treated (I) or not. At two weeks (a), the diabetic rats as a group, either not treated with insulin (D and DP) or treated with insulin (DI and DIP) had significantly elevated GFR compared with the non-diabetic rats (N and NP) (p < 0.05). At 4 weeks (bottom panel), only the insulin-treated diabetic rats (DI and DIP) had elevated GFR compared with the non-diabetic rats (N and NP) (p < 0.05) diabetic rats. The UAE of the insulin-treated diabetic rats normalised for GFR was not elevated above that of the non-diabetic rats. The GFR was not affected by ponalrestat in the nondiabetic rats, the diabetic rats or the insulin-treated diabetic rats (Fig.5) . The GFR in both the non-insulintreated and the insulin-treated diabetic rats was elevated above that of the non-diabetic rats at two weeks, but only that of the insulin-treated diabetic rats was elevated at 4 weeks. However, when the GFR was expressed in terms of body mass, the GFR of the non-insulin treated diabetic rats was significantly elevated compared with the nondiabetic rats at four weeks (Table 5 ). There was no tendency for ponalrestat to reduce the GFR expressed in relation to body weight (Table 5 ). There was no difference in GFR normalised for kidney weight between any of the six groups of rats (data not shown).
Glornerular sorbitol content in non-diabetic rats and rats after 2 weeks of diabetes induced by streptozotocin
The mean glomerular sorbitol content in four separate experiments, each comprising pooled glomeruli from six rats was 23.8 _+ 3.6 nmol/mg DNA for non-diabetic rats and 34.9 + 3.3 nmol/mg DNA (p < 0.05) for diabetic rats injected with STZ two weeks before. 229 Table 5 . Urinary albumin excretion (UAE) normalised for glomerular filtration rate (GFR) and GFR normalised for body mass in experiment 3. Mean_+ SEM are shown. There were six rats in each group UAE/GFR GFR/kg body Bg/ml.min ~ mass ml-min-l/kg This study has confirmed that inhibition of the enzyme aldose reductase by two structurally unrelated compounds partially prevents the increase in UAE observed in rats with diabetes induced by STZ [15, 17, 21, 22] . It has also confirmed the findings of Craven et al. [22] that the enhanced PG production by glomeruli isolated from STZ diabetic rats is reduced by treatment with ARI. No effect of an ARI (in this case ponalrestat) on GFR was observed. Hyperfiltration was seen in rats after two weeks of STZ diabetes, but this had subsided by four weeks when expressed on a per animal basis, although it remained elevated when corrected for body weight. Early hyperfiltration with subsequent fall to non-diabetic levels has been described previously in diabetic rats [4, [6] [7] [8] . The effect of suboptimal insulin treatment to prolong the hyperfiltration has also been observed previously [4, 6, 8] . The fact that insulin treatment of STZ-diabetic rats prevented the rise in UAE confirms that the increased UAE is not due to a toxic renal effect of STZ unrelated to diabetes. Unlike Triton et al. [17] and Bank et al. [28] , but similarly to Daniel and Hostetter [16] and Mauer et al. [29] , we found no effect of an ARI (in this case ponalrestat) on GFR [17] . The reason for this is not clear, but may be related to the type of ARI, its dose, the method of measurement of GFR or many other variables. Moreover, sorbinil appears to decrease single nephron blood flow but increase filtration fraction in STZ-diabetic rats [28] , and the balance between these two effects could vary in different experimental settings producing different net effects on GFR. However, in the present experiments, the clear lack of effect on GFR, with the simultaneous marked effect in diminishing UAE clearly establishes that the effect of the ARI on UAE is not mediated solely by an effect on GFR. This conclusion is supported by the data relating to the effect of suboptimal insulin therapy. As shown previously [6, 8] , this prolongs the period of hyperfiltration, but prevents the early increase in UAE. Moreover, the dissociation of hyperfiltration from increased UAE in the untreated diabetic rats is further reinforced by expressing the UAE normalised according to GFR (Table 5 ). When expressed in this way, UAE remains markedly elevated in the un-treated diabetic rats. It is in the non-diabetic range in the ponalrestat-treated diabetic rats.
In agreement with Craven et al. [22] , we have shown that sorbinil diminishes the increased glomerular PG production. However, we have been able to clarify some confusing aspects of the previous study. First, by showing that two structurally unrelated ARI shared this effect, the case for the effect being related to aldose reductase inhibition is strengthened. Moreover, unlike Craven et al. [22] , it was demonstrated that the glomerular sorbitol content is already elevated after two weeks of diabetes, making it likely (but certainly not proving) that the effect of the ARI was linked to inhibition of sorbitol formation (or some other aspect of inhibition of the aldose reductase pathway). The increased basal PGE and 6-keto-PGFla production, and the relatively small effect of exogenous arachidonic acid or angiotensin II on PG production in the glomeruli from the diabetic rats supports the conclusion of Craven et al. [30] that the increased glomerular PG synthesis in diabetes is due to increased arachidonate availability due to endogenous phospholipase A2 activation. If arachidonic acid is provided exogenously (as in Fig.3 ), or phospholipase A2 activated by exogenous angiotensin II (as in Table 3 ), the PG production from diabetic glomeruli is not greater than from control glomeruli.
The lack of correlation between the effect of ponalrestat on glomerular PG production (which is decreased) and on GFR (which is not affected) suggests that factors other than or in addition to PGs may mediate the hyperfiltration of diabetes, although without knowledge of the concentration response curve for endogenous PGs and GFR under the conditions of the study, this conclusion must be tentative. Obviously the relationship of glomerular PGs to GFR in diabetes is complex, as reflected by previous reports which have had conflicting results [10, 20, 23] .
In conclusion, the current study has shown that two structurally unrelated ARI reduce the elevated UAE observed in rats with short-term (two to four weeks) STZ-induced diabetes. This effect is apparently due to an effect on glomerular permeability rather than on GFR, which, in this study, was unaffected. Both agents reduced the increased glomerular PG production in the diabetic rats, but did not restore it to the level of the non-diabetic rats. It is thus clear that there are links between aldose reductase pathway activity, glomerular PG production and UAE, but the nature of the links, and cause and effect relationships remain to be established. It is also not clear whether the effect of the ARI is due to their effect on sorbitol levels, alteration of the cellular NADP: NADPH ratio or to effects unrelated to aldose reductase inhibition. The last possibility seems unlikely in view of the similar effects of structurally dissimilar ARI. The relevance of partial reversal of the early increased albumin excretion in induced acute diabetes in rats to the prevention of diabetic nephropathy in humans is also uncertain. However, despite all these reservations, the data support the concept that increased aldose reductase pathway activity is linked to the abnormalities of PG synthesis and albumin excretion observed in early diabetes, and that the changes are partially preventable by pharmacological agents.
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